Document Detail


Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
MedLine Citation:
PMID:  20679887     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The standard of care for resected stage II - IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin regimens. A recent meta-analysis (Lung Adjuvant Cisplatin Evaluation) showed no survival benefit for this modality in stage IB disease. Therefore, the role for stage IB disease remains controversial. The Lung Adjuvant Cisplatin Evaluation meta-analysis, which is based on pooled data of five randomized trials, has shown a 5.3% absolute survival benefit at 5 years. However, long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected non-small-cell lung cancer indicated a possible late adjuvant chemotherapy-related over-mortality. Tumor stage currently is the benchmark standard use for identifying patients who would benefit from adjuvant treatment. In the knowledge of late adjuvant chemotherapy-related over-mortality it is therefore critical to identify subsets of patients who would or would never benefit from adjuvant cisplatin. This review will discuss the extent to which individualized adjuvant treatment can be provided.
Authors:
Sandra Geiger; Marcus Schlemmer; Volker Heinemann; Hans Joachim Stemmler
Related Documents :
22263087 - Stereotactic ablative radiotherapy for stage i nsclc: recent advances and controversies.
19309717 - Congenital glioblastoma.
20097087 - The influences of age and co-morbidities on treatment decisions for patients with her2-...
20336787 - Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a populatio...
2092097 - Drainage of aspergillus "primitive" brain abscess with long-term survival. case report.
12530027 - Does p-glycoprotein-170 expression predict for chemoresistance in transitional cell car...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  21     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  799-804     Citation Subset:  IM    
Affiliation:
Medical Department III, Ludwig-Maximilians University of Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Chemotherapy, Adjuvant / methods
Cisplatin / administration & dosage
Humans
Lung Neoplasms / drug therapy*,  pathology
Neoplasm Staging
Randomized Controlled Trials as Topic
Survival
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive card...
Next Document:  Statistical identification of predictors for peripheral neuropathy associated with administration of...